August 19, 2023

The FDA OK’d a high-dose ver­sion of Re­gen­eron’s eye dis­ease in­jectable Eylea on Fri­day evening just two months af­ter de­fi­cien­cies at the bio­phar­ma’s third-par­ty man­u­fac­tur­er

When fam­i­ly doc­tor Bri­an Koff­man found some bumps on the back of his neck, he ran some tests on him­self. Every­thing checked out ex­cept his

The FDA ap­proved Re­gen­eron’s poze­limab, the first treat­ment for a rare, hered­i­tary im­mune dis­ease that af­fects few­er than 100 peo­ple world­wide. The mon­o­clon­al an­ti­body, to

The AARP on Fri­day filed an am­i­cus brief ask­ing a judge to up­hold the In­fla­tion Re­duc­tion Act, ar­gu­ing that stop­ping the drug price ne­go­ti­a­tion pro­gram

Wel­come to the lat­est phar­ma mar­ket­ing hot spot — physi­cians’ liv­ing rooms. Doc­tors are watch­ing TV at home just like every­one else, but not on­ly

Mer­ck said Fri­day morn­ing that its HIF-2α in­hibitor Welireg met the co-pri­ma­ry end­point of pro­gres­sion-free sur­vival in a Phase III tri­al for pa­tients with ad­vanced

Mod­er­na said that pre­lim­i­nary da­ta in hu­mans on its up­dat­ed Covid-19 vac­cine sug­gest it would be ef­fec­tive against vari­ants that are ex­pect­ed to cir­cu­late this

TFC Ther­a­peu­tics, a new ARCH Ven­ture Part­ners biotech, on Thurs­day un­veiled a mis­sion to thwart the re­turn of can­cer and its spread to oth­er parts of